Fish§ssup§+§esup§CD34§ssup§+§esup§ CD38§ssup§-§esup§ cells detected in newly diagnosed acute myeloid leukemia patients can predict the clinical outcome

Journal of Hematology and Oncology

Volumn 6, Issue 1, 2013, Pages

  Wang, Libing ^a   Gao, Lei ^a   Xu, Sheng ^a   Gong, Shenglan ^a   Chen, Li ^a   Lü, Shuqing ^a   Chen, Jie ^a   Qiu, Huiying ^a   Xu, Xiaoqian ^a   Ni, Xiong ^a   Song, Xianmin ^a   Zhang, Weiping ^a   Yang, Jianmin ^a   Liu, Min ^a   Hu, Xiaoxia ^a   Wang, Jianmin ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Acute myeloid leukemia; Leukemia initiating cells; Minimal residual disease

Indexed keywords

CD34 ANTIGEN; CD38 ANTIGEN; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IDARUBICIN; METHOTREXATE; ANTINEOPLASTIC AGENT;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ANTIGEN DETECTION; ARTICLE; BLAST CELL; CANCER PROGNOSIS; CD34 SELECTION; CLINICAL ARTICLE; CONSOLIDATION CHEMOTHERAPY; CONTINUOUS INFUSION; CYTOGENETICS; EVENT FREE SURVIVAL; FEBRILE NEUTROPENIA; FEMALE; FLOW CYTOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; HUMAN; INDUCTION CHEMOTHERAPY; INFECTION; KARYOTYPE; LEUKEMIA CELL; LEUKEMIA INITIATING CELL; LEUKEMIA RELAPSE; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; SEPSIS; T LYMPHOCYTE SUBPOPULATION; TREATMENT OUTCOME; TREATMENT RESPONSE; BIOSYNTHESIS; CANCER STEM CELL; GENETICS; IMMUNOPHENOTYPING; METABOLISM; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOLOGY; PROGNOSIS; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIGENS, CD34; ANTIGENS, CD38; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOPHENOTYPING; IN SITU HYBRIDIZATION, FLUORESCENCE; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASTIC STEM CELLS; PROGNOSIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84887115053     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/1756-8722-6-85     Document Type: Article

References (22)

1. Anthracycline dose intensification in acute myeloid leukemia. Fernandez HF, Sun Z, Yao X, Litzow MR, Luger SM, Paietta EM, Racevskis J, Dewald GW, Ketterling RP, Bennett JM, Rowe JM, Lazarus HM, Tallman MS, N Engl J Med 2009 361 1249 1259 10.1056/NEJMoa0904544 19776406
2. Acute myeloid leukemia (AML): different treatment strategies versus a common standard arm-combined prospective analysis by the German AML intergroup. Buchner T, Schlenk RF, Schaich M, Dohner K, Krahl R, Krauter J, Heil G, Krug U, Sauerland MC, Heinecke A, Spath D, Kramer M, Scholl S, Berdel WE, Hiddemann W, Hoelzer D, Hehlmann R, Hasford J, Hoffmann VS, Dohner H, Ehninger G, Ganser A, Niederwieser DW, Pfirrmann M, J Clin Oncol 2012 30 3604 3610 10.1200/JCO.2012.42.2907 22965967
3. Detectable minimal residual disease before hematopoietic cell transplantation is prognostic but does not preclude cure for children with very-high-risk leukemia. Leung W, Pui CH, Coustan-Smith E, Yang J, Pei D, Gan K, Srinivasan A, Hartford C, Triplett BM, Dallas M, Pillai A, Shook D, Rubnitz JE, Sandlund JT, Jeha S, Inaba H, Ribeiro RC, Handgretinger R, Laver JH, Campana D, Blood 2012 120 468 472 10.1182/blood-2012-02-409813 22517895
4. Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial. Yin JA, O'Brien MA, Hills RK, Daly SB, Wheatley K, Burnett AK, Blood 2012 120 2826 2835 10.1182/blood-2012-06-435669 22875911
5. Current findings for recurring mutations in acute myeloid leukemia. Takahashi S, J Hematol Oncol 2011 4 36 10.1186/1756-8722-4-36 21917154
6. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Bonnet D, Dick JE, Nat Med 1997 3 730 737 10.1038/nm0797-730 9212098 (Pubitemid 27298715)
7. Stem cell gene expression programs influence clinical outcome in human leukemia. Eppert K, Takenaka K, Lechman ER, Waldron L, Nilsson B, van Galen P, Metzeler KH, Poeppl A, Ling V, Beyene J, Canty AJ, Danska JS, Bohlander SK, Buske C, Minden MD, Golub TR, Jurisica I, Ebert BL, Dick JE, Nat Med 2011 17 1086 1093 10.1038/nm.2415 21873988
8. A clinically relevant population of leukemic CD34(+)CD38(-) cells in acute myeloid leukemia. Gerber JM, Smith BD, Ngwang B, Zhang H, Vala MS, Morsberger L, Galkin S, Collector MI, Perkins B, Levis MJ, Griffin CA, Sharkis SJ, Borowitz MJ, Karp JE, Jones RJ, Blood 2012 119 3571 3577 10.1182/blood-2011-06-364182 22262762
9. High levels of CD34 + CD38low/-CD123+ blasts are predictive of an adverse outcome in acute myeloid leukemia: a groupe ouest-Est des leucemies aigues et maladies du sang (GOELAMS) study. Vergez F, Green AS, Tamburini J, Sarry JE, Gaillard B, Cornillet-Lefebvre P, Pannetier M, Neyret A, Chapuis N, Ifrah N, Dreyfus F, Manenti S, Demur C, Delabesse E, Lacombe C, Mayeux P, Bouscary D, Recher C, Bardet V, Haematologica 2011 96 1792 1798 10.3324/haematol.2011.047894 21933861
10. The novel AML stem cell associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells. van Rhenen A, van Dongen GA, Kelder A, Rombouts EJ, Feller N, Moshaver B, Stigter-van Walsum M, Zweegman S, Ossenkoppele GJ, Jan Schuurhuis G, Blood 2007 110 2659 2666 10.1182/blood-2007- 03-083048 17609428 (Pubitemid 47523190)
11. Residual normal stem cells can be detected in newly diagnosed chronic myeloid leukemia patients by a new flow cytometric approach and predict for optimal response to imatinib. Janssen JJ, Deenik W, Smolders KG, van Kuijk BJ, Pouwels W, Kelder A, Cornelissen JJ, Schuurhuis GJ, Ossenkoppele GJ, Leukemia 2012 26 977 984 10.1038/leu.2011.347 22157734
12. High proportion of leukemic stem cells at diagnosis is correlated with unfavorable prognosis in childhood acute myeloid leukemia. Witte KE, Ahlers J, Schafer I, Andre M, Kerst G, Scheel-Walter HG, Schwarze CP, Pfeiffer M, Lang P, Handgretinger R, Ebinger M, Pediatr Hematol Oncol 2011 28 91 99 10.3109/08880018.2010.528171 21214408
13. High stem cell frequency in acute myeloid leukemia at diagnosis predicts high minimal residual disease and poor survival. van Rhenen A, Feller N, Kelder A, Westra AH, Rombouts E, Zweegman S, van der Pol MA, Waisfisz Q, Ossenkoppele GJ, Schuurhuis GJ, Clin Cancer Res 2005 11 6520 6527 10.1158/1078-0432.CCR-05- 0468 16166428 (Pubitemid 41338990)
14. Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. Cheson BD, Bennett JM, Kopecky KJ, Buchner T, Willman CL, Estey EH, Schiffer CA, Doehner H, Tallman MS, Lister TA, Lo-Coco F, Willemze R, Biondi A, Hiddemann W, Larson RA, Lowenberg B, Sanz MA, Head DR, Ohno R, Bloomfield CD, J Clin Oncol 2003 21 4642 4649 10.1200/JCO.2003.04.036 14673054 (Pubitemid 46594039)
15. Censoring distributions as a measure of follow-up in survival analysis. Korn EL, Stat Med 1986 5 255 260 10.1002/sim.4780050306 3738291
16. Non-parametric inference for cumulative incidence functions in competing risks studies. Lin DY, Stat Med 1997 16 901 910 10.1002/(SICI)1097- 0258(19970430)16:8<901::AID-SIM543>3.0.CO;2-M 9160487 (Pubitemid 27198953)
17. Impact of molecular prognostic factors in cytogenetically normal acute myeloid leukemia at diagnosis and relapse. Walker A, Marcucci G, Haematologica 2011 96 640 643 10.3324/haematol.2011.042739 21531946
18. Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia. Jourdan E, Boissel N, Chevret S, Delabesse E, Renneville A, Cornillet P, Blanchet O, Cayuela JM, Recher C, Raffoux E, Delaunay J, Pigneux A, Bulabois CE, Berthon C, Pautas C, Vey N, Lioure B, Thomas X, Luquet I, Terre C, Guardiola P, Bene MC, Preudhomme C, Ifrah N, Dombret H, Blood 2013 121 2213 2223 10.1182/blood-2012-10-462879 23321257
19. Downstream molecular pathways of FLT3 in the pathogenesis of acute myeloid leukemia: biology and therapeutic implications. Takahashi S, J Hematol Oncol 2011 4 13 10.1186/1756-8722-4-13 21453545
20. Mutations in ASXL1 are associated with poor prognosis across the spectrum of malignant myeloid diseases. Gelsi-Boyer V, Brecqueville M, Devillier R, Murati A, Mozziconacci MJ, Birnbaum D, J Hematol Oncol 2012 5 12 10.1186/1756-8722-5-12 22436456
21. Aberrant marker expression patterns on the CD34 + CD38- stem cell compartment in acute myeloid leukemia allows to distinguish the malignant from the normal stem cell compartment both at diagnosis and in remission. van Rhenen A, Moshaver B, Kelder A, Feller N, Nieuwint AW, Zweegman S, Ossenkoppele GJ, Schuurhuis GJ, Leukemia 2007 21 1700 1707 10.1038/sj.leu.2404754 17525725 (Pubitemid 47086760)
22. Image cytometry-based detection of aneuploidy by fluorescence in situ hybridization in suspension. Minderman H, Humphrey K, Arcadi JK, Wierzbicki A, Maguire O, Wang ES, Block AW, Sait SN, George TC, Wallace PK, Cytometry A 2012 81 776 784 22837074 China